AQB vs PACB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PACB Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Pacific Biosciences of California, Inc. (PACB) driven by superior Momentum & Technical, Options & Structure while AQB counters with relative strength in Growth & Margin. Fundamentally, AQB trades at N/M Forward P/E with 0.0% operating margin (-93.5% YoY revenue) versus PACB at N/M Forward P/E and -333.0% operating margin (+5.5% YoY). In options structure, AQB sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against PACB sits in BREAKDOWN (97th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AQB Revenue | PACB Revenue | AQB Op. Margin | PACB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $80M | -12264.6% | -128.4% | PACB |
| FY2019 | $0M | $90M | -7057.3% | -110.6% | PACB |
| FY2020 | $0M | $80M | -12727.1% | -132.3% | PACB |
| FY2021 | $0M | $130M | -1883.0% | -161.2% | PACB |
| FY2022 | $0M | $130M | -711.6% | -239.4% | PACB |
| FY2023 | $0M | $200M | -552.9% | -166.8% | PACB |
| FY2024 | N/A | $150M | N/A | -308.0% | PACB |
| FY2025 | N/A | $160M | N/A | -346.2% | PACB |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AQB | PACB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $9.7M | $574.5M | Larger Scale | PACB |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -93.5% | +5.5% | Higher Growth | PACB |
| Operating Margin (TTM) Profitability | 0.0% | -333.0% | Higher Margin | AQB |
| Net Profit Margin Profitability | 0.0% | -81.3% | Higher Margin | AQB |
| Return on Equity (ROE) Capital Efficiency | -68.9% | -929.3% | Higher ROE | AQB |
| 52-Week Range Position Momentum | 11% ($1โ$2) | 32% ($1โ$3) | Stronger Trend | PACB |
| Beta / 30D Volatility Risk Regime | 0.93ฮฒ ยท 117% Vol | 2.24ฮฒ ยท 109% Vol | Lower Realized Risk | PACB |
| Unified Institutional Score Composite Signal | 44.6 / 100 (HOLD) | 50.1 / 100 (HOLD) | Higher Composite | PACB |